1433 related articles for article (PubMed ID: 19584156)
1. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
3. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
4. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
5. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
7. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
8. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
10. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
Sas S; Chan T; Sami A; El-Gayed A; Xiang J
Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
[TBL] [Abstract][Full Text] [Related]
14. [Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].
Ma SD; Luo RC; Ding ZH; Lu F; Yuan CQ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1184-7. PubMed ID: 16939917
[TBL] [Abstract][Full Text] [Related]
15. Immortalized dendritic cell line with efficient cross-priming ability established from transgenic mice harboring the temperature-sensitive SV40 large T-antigen gene.
Ebihara S; Endo S; Ito K; Ito Y; Akiyama K; Obinata M; Takai T
J Biochem; 2004 Sep; 136(3):321-8. PubMed ID: 15598888
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
Saha A; Chatterjee SK
Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
[TBL] [Abstract][Full Text] [Related]
17. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
Dela Cruz JS; Morrison SL; Penichet ML
Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
Kim JH; Majumder N; Lin H; Chen J; Falo LD; You Z
Mol Ther; 2005 Jun; 11(6):941-9. PubMed ID: 15922965
[TBL] [Abstract][Full Text] [Related]
20. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
